Several studies have demonstrated that exposure therapy - in which the patient is exposed to specific feared situations or objects that trigger anxiety - is an effective way to treat anxiety disorders. However, to overcome a number of limitations inherent in this approach - lack of full control of the situation, costs and time required, etc. - some therapists have started to add virtual reality (VR) to the in vivo exposure-based therapy, providing in-office, controlled exposure therapy. Compared to the in vivo exposure, VR Exposure Therapy (VRET) is completely controlled: the quality, the intensity and the frequency of the exposure are decided by the therapist, and the therapy can be stopped at any time if the patient does not tolerate it. Moreover, the flexibility of a virtual experience allows the patient to experience situations that are often much worse and more exaggerated than those that are likely to be encountered in real life. However, a critical issue underlying the use of VRET in the treatment of anxiety-related disorders is the lack of a virtual reality system in the patient's real-life context. In this paper, we present a clinical protocol for the treatment of Generalized Anxiety Disorders (GAD) based on the ubiquitous use of a biofeedback-enhanced VR system. The protocol includes the use of a mobile exposure system allowing patients to perform the virtual experience in an outpatient setting. A between-subjects study, involving 25 GAD patients, was carried out to verify the efficacy of the proposed approach. The clinical data in this pilot study seemed to support the efficacy of the ubiquitous approach. © 2011 Springer-Verlag London Limited.

Repetto, C., Gaggioli, A., Pallavicini, F., Cipresso, P., Raspelli, S., & Riva, G. (2013). Virtual reality and mobile phones in the treatment of generalized anxiety disorders: a phase-2 clinical trial. PERSONAL AND UBIQUITOUS COMPUTING, 17(2), 253-260 [10.1007/s00779-011-0467-0].

Virtual reality and mobile phones in the treatment of generalized anxiety disorders: a phase-2 clinical trial

PALLAVICINI, FEDERICA;CIPRESSO, PIETRO;RASPELLI, SIMONA;
2013

Abstract

Several studies have demonstrated that exposure therapy - in which the patient is exposed to specific feared situations or objects that trigger anxiety - is an effective way to treat anxiety disorders. However, to overcome a number of limitations inherent in this approach - lack of full control of the situation, costs and time required, etc. - some therapists have started to add virtual reality (VR) to the in vivo exposure-based therapy, providing in-office, controlled exposure therapy. Compared to the in vivo exposure, VR Exposure Therapy (VRET) is completely controlled: the quality, the intensity and the frequency of the exposure are decided by the therapist, and the therapy can be stopped at any time if the patient does not tolerate it. Moreover, the flexibility of a virtual experience allows the patient to experience situations that are often much worse and more exaggerated than those that are likely to be encountered in real life. However, a critical issue underlying the use of VRET in the treatment of anxiety-related disorders is the lack of a virtual reality system in the patient's real-life context. In this paper, we present a clinical protocol for the treatment of Generalized Anxiety Disorders (GAD) based on the ubiquitous use of a biofeedback-enhanced VR system. The protocol includes the use of a mobile exposure system allowing patients to perform the virtual experience in an outpatient setting. A between-subjects study, involving 25 GAD patients, was carried out to verify the efficacy of the proposed approach. The clinical data in this pilot study seemed to support the efficacy of the ubiquitous approach. © 2011 Springer-Verlag London Limited.
Articolo in rivista - Articolo scientifico
Scientifica
virtual reality; mobile phones; anxiety disorders; stress
English
253
260
8
Repetto, C., Gaggioli, A., Pallavicini, F., Cipresso, P., Raspelli, S., & Riva, G. (2013). Virtual reality and mobile phones in the treatment of generalized anxiety disorders: a phase-2 clinical trial. PERSONAL AND UBIQUITOUS COMPUTING, 17(2), 253-260 [10.1007/s00779-011-0467-0].
Repetto, C; Gaggioli, A; Pallavicini, F; Cipresso, P; Raspelli, S; Riva, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/49415
Citazioni
  • Scopus 82
  • ???jsp.display-item.citation.isi??? 69
Social impact